Cancer, Late-line clear cell renal cell carcinoma (ccRCC)
RCUSArcus BiosciencesCatalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for Casdatifan (AB521) (HIF-2a Inhibitor) in Cancer, Late-line clear cell renal cell carcinoma (ccRCC). The expected timing is based on the latest available company guidance and may change.
ARC-20 trial monotherapy cohorts. 12/12/25:- Early 2026 analyses incl updated PFS for 100mg QD late-line ccRCC cohort. 02/23/26:- Ph1 ARC-20 late-line ccRCC update: 45% cORR, 15.1-month mPFS for 100mg QD at ASCO-GU 2026. 02/25/26:- ARC-20 late-line ccRCC: updated ORR, PFS, pooled analysis and biomarker correlations; safety profile remains consistent with prior casdatifan data. 05/05/26:- ARC-20 late-line monotherapy cohorts will provide updated data including overall survival in 2026. 08/05/26:- ARC-20 late-line monotherapy OS data expected in H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.